不同的给药途径防治后发性白内障  

Different routes of drug administration in treatment of posterior capsule opacification

作　　者：向建南[1,2] 王国华[3] 张海江[3] 霍鸣[1,2,3] 

机构地区：[1]三峡大学医学院 [2]三峡大学第一临床医学院眼科,中国湖北省宜昌市443003 [3]中国湖北省宜昌市中心人民医院眼科,443003

出　　处：《国际眼科杂志》2010年第6期1092-1094,共3页International Eye Science

摘　　要：后发性白内障是白内障囊外摘出联合人工晶状体植入术后最常见的并发症,术后残留的晶状体上皮细胞是其发生的关键因素,防治后发性白内障最重要问题是抑制晶状体上皮细胞增殖和迁移,这类似于肿瘤的治疗,因此,选择最佳给药途径以维持药物有效浓度并减少其毒副作用,是研究的难点,我们就防治后发性白内障的药物的给药途径进行综述。Posterior capsule opacification（PCO） is a subsequent complication after the implantation of the artificial lens from the extracapsular cataract extraction. The lens epithelial cells after the operation play the key factors. The most important way to treat PCO is to avoid the growth and transposition of the lens epithelial cells,which is similar to the treatment of the tumor. So, the difficulty in the study is how to choose the best method of drug administration which can keep the effective concentration of the drug and reduce its side effect. This thesis summarizes the routes of drug administration in the treatment of PCO.

关 键 词：后发性白内障 防治 晶状体上皮细胞 

分 类 号：R776.1[医药卫生—眼科]